Form 4: Corcept Director Sells Shares After Option Exercise

Corcept Therapeutics director Daniel N. Swisher Jr. exercised stock options and immediately sold 2,200 shares of common stock for $87.54 per share.

Summary

• Director Daniel N. Swisher Jr. engaged in a transaction involving Corcept Therapeutics Inc. (CORT) common stock.
• On October 10, 2025, Swisher exercised stock options to acquire 2,200 shares of common stock at an exercise price of $14.08 per share.
• Immediately following the exercise on the same date, Swisher sold all 2,200 newly acquired shares of common stock at a price of $87.54 per share.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Swisher on August 1, 2024.
• Following these transactions, Swisher directly owns 0 shares of common stock and 1,100 stock options.

Sentiment

Score: 6

Explanation: The transaction represents a planned exercise of options and sale of shares by a director under a Rule 10b5-1 plan. While an insider sale can sometimes be viewed negatively, the pre-planned nature mitigates concerns about immediate negative sentiment. The director realized a substantial profit, which is positive for the individual.

Positives

• Director Daniel N. Swisher Jr. realized a significant gain from exercising options at $14.08 and selling shares at $87.54.
• The transaction was executed under a pre-arranged 10b5-1 plan, indicating a planned disposition rather than an immediate reaction to new information.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence in future stock price appreciation, though this is not always the case for planned sales.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale by a director, even if planned, might be viewed with slight caution by some, but the pre-planned nature under 10b5-1 reduces the implication of new negative information.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (option exercise and sale) by a director. It does not provide new fundamental information about Corcept Therapeutics' operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction was executed under a 10b5-1 plan, which suggests it's a scheduled event rather than a reaction to new, undisclosed information. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a compelling reason to buy or sell based on new company-specific insights.

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Daniel N. Swisher Jr., 10b5-1 Plan, Director Transaction